Form 4: Prelude Therapeutics CEO Krishna Vaddi Acquires 10,000 Shares of Common Stock

Prelude Therapeutics CEO Krishna Vaddi reports the acquisition of 10,000 shares of common stock at $1.20 per share on December 30, 2024.

Summary

• On December 30, 2024, Krishna Vaddi, CEO of Prelude Therapeutics Inc., acquired 10,000 shares of common stock at a price of $1.20 per share.
• Following this transaction, Vaddi directly owns 1,167,275 shares of common stock.
• Vaddi also has indirect ownership through various trusts: 137,553 shares via Sidus Ventures LLC, 551,776 shares via Blue Sky Trust, 551,774 shares via Brocade Trust, and 423,665 shares via Dolphin City Trust.
• Vaddi disclaims beneficial ownership of shares held by Sidus Ventures LLC, Blue Sky Trust, Brocade Trust and Dolphin City Trust except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock acquisition by the CEO. The purchase itself could be seen as slightly positive, but the document is primarily informational.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal about their confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates